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Assessment of plasma and urinary transforming growth factor beta 1 




Systemic lupus erythematosus (SLE) is a 
generalized autoimmune disorder characterized by 
T and B cell hyperactivity with autoantibodies 
against numerous cell components and deposition 
of immune complexes. The disease has a 
multifactorial pathogenesis with genetic, hormonal 
and environmental components1,2. 
In autoimmune diseases, infiltration with T 
cells or deposition of autoantibody-containing 
immune complexes in target organs, such as 
kidneys, causes early inflammatory lesions. The 
early immune mediated injury is believed to trigger 
a series of events, including complement activation, 
chemokine production, further inflammatory cell 
infiltration, and inflammatory cytokine release, 
eventually resulting in deposition of extracellular 
matrix3.  
Original article 
Background: Kidney disease is one of the most serious manifestations of 
systemic lupus erythematosus (SLE). Despite the improvement in the medical 
care of SLE in the past two decades, the prognosis of lupus nephritis remains 
unsatisfactory. Transforming growth factor- β1 (TGF-β1) is an immuno-
suppressive cytokine, as it inhibits T and B cell proliferation and NK cell 
cytotoxic activity . 
Objective: The aim of this study was to assess serum and urinary TGF- β1 levels 
in children with SLE and their possible role in the renal involvement and 
activity of the disease. 
Study design: This cross sectional study was conducted in Nephrology Unit of 
Pediatric Department, plus Outpatient Clinic of Rheumatology Department , 
Zagazig University Hospital during the year of 2010. 
Methods: Twenty-five pediatric patients with SLE were randomly selected and 
classified according to into 2 groups: Group (Ι): included 13 patients presented 
with urinary abnormalities and/or disturbed renal function(active nephritis): 5
males, 8 females. Their mean age was 9.7±2.53 years and the mean disease 
duration was 2.46±1.4 years. Group (ΙΙ): included 12 patients presented by 
lupus without nephritis : 5 males,7 females. Their mean age was 9.9±2.1 years 
and the mean disease duration was 2.41±0.9 years. Control group(group ΙΙΙ):
Twenty healthy children of matched age and sex served as a control group 
included  8 males ,12 females. Their mean age was 10.0±2.3 years. 
Results: There was no significant difference among studied patients groups 
regarding age, sex , disease duration and lupus therapy (p>0.05). There was a 
significant difference between both groups  regarding urinary albumin and 
serum creatinine (2.76±0.97 and  1.96±0.84 mg/dl respectively) ,while there was 
a high significant difference between them regarding C3 (47.3±12.5 and 
76.6±6.6 mg/ml respectively) and anti double stranded DNA (anti-dsDNA) 
(80.7±32.8 and 26.8±4.5 IU/ml respectively). Plasma TGF- β1 showed 
significantly lower levels in patients with active nephritis relative to other 
groups, while urinary TGF- β1 levels were significantly high in SLE patients 
either with active or silent nephritis when compared with the control group.
Plasma TGF- β1 showed a highly significant positive correlation with C3 and a 
highly significant negative correlation with serum creatinine, urinary albumin, 
anti dsDNA and SLE disease activity index (SLEDAI) score. While, urinary 
TGF- β1 had a significant negative correlation with C3 and a high significant 
positive correlation with anti-dsDNA and SLEDAI score. 
Conclusion: Low plasma TGF β1 level and increased urinary TGF β1 excretion 
denotes active renal affection in children with SLE . 
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Detection of antinuclear antibodies in serum is 
one of the most frequent laboratory tests for 
diagnosis of SLE. Anti dsDNA antibodies are 
considered a hallmark of SLE and anti-Sm 
antibodies have a significant association with lupus 
nephritis. However, not all anti-dsDNA antibodies 
can deposit in the kidney, nor has it been possible to 
replicate the disease of lupus nephritis with passive 
transfer of anti-dsDNA  antibodies4.  
Transforming growth factor- β1(TGFβ1) affects 
differentiation, inhibits proliferation and induces 
apoptosis of B and T cells, and it is an important 
costimulator generating regulatory CD4 +CD25+ 
and CD8+ T cells, that help to maintain tolerance 
against self and non-self antigens. It was originally 
isolated from platelets but has also been found in 
cell cultures of monocytes/macrophages and renal 
mesangial cells5,6. 
Normally, the release of TGF- β1 is controlled 
by a feedback mechanism when the healing process 
has been completed. However, if its release is not 
switched off, extracellular matrix components are 
accumulated and tissue fibrosis occurs. Renal TGF- 
β1 is a key mediator of glomerular and 
tubulointerstitial pathology in renal diseases7. 
The aim of this study was to assess plasma and 
urinary TGF- β1 levels in children with SLE and 
their possible role in the renal involvement and 
activity of the disease. 
 
METHODS 
This study was a cross-sectional one  conducted in 
Pediatric department, Nephrology Unit plus 
Outpatient Clinic of Rheumatology Department, 
Zagazig University Hospital during the year of 
2010. 
Patient groups 
Included 25 pediatric patients fulfilling the 1997 
revised classification criteria of American 
Rheumatism Association for SLE8. The clinical 
disease activity for each patient with SLE was 
scored using the SLE disease activity index 
(SLEDAI)9. Patients were designated to be disease-
active when their major clinical manifestations were 
present or SLEDAI was>319. Patients presented 
with renal disorders were subjected to renal biopsy 
for histopathologic classification using WHO 
classification system10. The criterion for the 
diagnosis of renal disorder included the presence of: 
a)persistent proteinuria 0.5 gm/24h (or more than 
+3 dipstick reaction for albumin), or b) cellular 
casts including: red blood cell, granular, renal 
tubular or mixed11. 
According to presence of clinical 
manifestations of renal affection, abnormal urinary 
findings and renal biopsy staging, patients were 
classified into two groups: 
Group (Ι): included 13 patients with active 
nephritis: 5 males, 8 females. Their mean age was 
9.7±2.53 years and the mean disease duration was 
2.46±1.4 years. Renal biopsy results denoted that: 2 
(15.4%) patients were in class Ι, 4 (30.8%) in class 
ΙΙ, while class ΙΙΙ  and IV were present in 3 and 4 
patients respectively. 
Group (ΙΙ): included 12 patients without clinical or 
laboratory renal affection (lupus without nephritis): 
5 males, 7 females. Their mean age was 9.9±2.1 
years and the mean disease duration was 2.41±0.9 
years. 
Control group (ΙΙΙ): Twenty healthy children of 
matched age and sex served as a control group. It 
included: 8 males,12 females. Their mean age was 
10.0±2.3 years). 
Ethical approval was obtained from the local 
research ethics committee and parents of all 
subjects gave an informed written consent prior to 
the study.  
All patients were subjected to: 
- Thorough  clinical examination 
- Laboratory investigations including: 
1. Complete blood count (SYSMEX K1000 
Automated hematology analyzer). 
2. Liver and Kidney function (ADVIA 1650 
Autoanalyzer Siemens medical solution 
diagnostic). 
3. Complete urine analysis. 
4. Detection of serum anti-ds DNA by ELISA 
technique ( Diagnostic Automation  Inc). 
5. Detection of serum C3 by Radial immuno 
diffusion (Binding Site LtD  KIT , UK). 
6. TGF-β1 levels (in plasma and urine) were 
measured by ELISA . 
Sample collection 
Blood samples were obtained by sterile 
venipuncture , two  mls of blood were delivered 
into an EDTA tube  and centrifuged to obtain 
plasma for detection of TGF-β1.  
Serum samples were   separated  from  three  ml of 
blood  and  kept at -70°C used for assay of  anti-ds 
DNA and C3.   
Aseptically  collected  random urine sample was 
taken and centrifuged to remove particulates, was 
used  for  assay  of  TGF-β1.  
TGF β1 assay used monoclonal antibody  as capture 
antibody and  biotinylated polyclonal antibody as 
detection antibody (BD Biosciences Pharmingen, 
San Diego, US). The assay specifically measures 
active TGF-β1 forms. To measure total TGF-β1, 
biologically latent TGF was activated by acid-
treatment.  For this purpose, samples were diluted 
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with four volumes of Phosphate-buffered saline. 
Samples were then incubated in the presence of 1N 
HCl , then neutralized with equal volume of 1N Na 
OH .ELISA analysis was performed in 96-well 
plates following the instructions of the 
manufacturer . Recombinant human TGF-β1 (BD 
Biosciences Pharmingen, San Diego, US) was used 
as a standard .  
 
Statistical methods 
The data of the study was statistically  analysed   by 
SPSS (Statistical Package for Social Science) 
(Version 15). Difference in the level of TGF-β1 
between different groups was assessed by the use of 
ANOVA test. Spearman correlation coefficient was 
used for correlation of the quantitative variables. 
Chi squared test, student t-test and Mann Whitney 
(MW) test  were used for comparison between the 




Table (1) shows demographic data of studied 
groups. There was no significant difference among 
studied groups regarding age , sex, disease duration 
and therapy (p>0.05). 
Table (2) shows clinical characteristics of 25 
patients with SLE. Most of the patients (72%) 
presented with cutaneous manifestations, 60% 
presented with arthralgia or arthritis, 52% had  renal 
manifestations (hematuria, persistent proteinuria, 
disturbed renal functions). Nervous system, 
gastrointestinal, cardiovascular and pulmonary 
involvements were present in 24, 20, 16 and 8 % of 
patients respectively. Five patients (20%) were 
presented with malaise and fever, while 3 children 
(12%) had splenomegaly, hepatomegaly or 
lymphadenopathy.  
Table (3) shows laboratory markers and 
SLEDAI score in lupus patients with active and 
without nephritis. There was a significant difference 
between both groups  regarding urinary albumin 
and serum creatinine (2.76±0.97 vs 1.96±0.84 
mg/dl). While there was a high significant 
difference between them regarding C3 (47.3±12.5 
vs 76.6±6.6 mg/ml) and anti dsDNA (80.7±32.8 vs 
26.8±4.5 IU/ml). Group (Ι) showed a significantly 
higher SLEDAI score than group ΙΙ (38.5±11.4 vs 
28.6±9.4). 
Table (4) shows plasma and urinary TGF-β1 in 
studied subjects. There was a highly significant 
difference between them regarding both plasma and 
urinary TGF-β1. Plasma TGF-β1 level showed 
significantly lower levels in patients  with active 
nephritis relative to other groups. While, urinary 
TGF-β1 levels were significantly high in SLE 
patients either with active or silent nephritis when 
compared with the control group.   
Table (5) shows correlation between plasma 
TGF-β1 and other laboratory parameters. There was 
a highly significant positive correlation with C3 and 
a high significant negative correlation with serum 
creatinine, urinary albumin, anti ds-DNA and 
SLEDAI score. 
Table (6) shows correlation between urinary 
TGF-β1 and other laboratory parameters. There was 
a highly significant negative correlation with C3 
and a highly significant positive correlation with 
anti-dsDNA and SLEDAI score. While, there was 
no significant correlation with serum creatinine, 
urinary albumin.  
 
Table 1. Demographic data of studied groups. 
 Group (Ι) 




































































-  χ 2=0.66 
 
0.8
p>0.05 non significant, * p<0.05 significant, ** p≤0.001 highly significant 
S: steroid (Prednisolone, Medrol), I: immunosuppressive drugs (Imuran, Sandimmune), C: cytotoxic drugs (Methotrexate) 
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Cutaneous and mucous membrane lesions 18 72 
Arthralgia and/or arthritis 15 60 
Renal manifestations (hematuria, persistent proteinuria, 
disturbed renal functions) 
13 52 
Central and/or peripheral nervous system involvement 6 24 
Gastrointestinal disorders 5 20 
Malaise, fever 5 20 
Cardiovascular disorders and Raynaud’s phenomenon 4 16 
Lymphadenopathy, splenomegaly, Hepatomegaly 3 12 




Table 3. Laboratory criteria and SLEDAI score in patients with active and silent lupus nephritis. 
 Group (Ι) 






























































χ 2=11.65 0.02* 
SLEDAI score 













Table 4. Plasma and urinary TGF- β1 in the studied subjects: 
 Group (Ι) 









(n = 20) 
F p 
P. TGF-β1 (pg/ml) 















U. TGF-β1 (ng/ml) 















* p<0.05 significant,** p≤0.001 highly significant 
aSignificant difference between active and silent nephritis. 
bSignificant difference active nephritis and the control. 
c Significant difference silent nephritis and the control. 
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Table 5. Correlation between plasma TGF-β1 
and other laboratory parameters. 
Table 6. Correlation between urinary TGF-β1 
and other laboratory parameters. 
P. TGF-β1 (pg/ml) r p Sig.
Anti-dsDNA (IU/ml) -0.85 <0.001** HS 
C3 (mg/ml) 0.88 <0.001** HS 
S. creatinine (mg/dl) -0.44 <0.05 Sig.
Urinary albumin -0.55 <0.001** HS 
SLEAI score -0.83 <0.001** HS  
U. TGF-β1 (ng/ml) r p Sig. 
Anti-dsDNA (IU/ml) 0.71 <0.001** HS 
C3(mg/ml) -0.64 <0.001** HS 
S. creatinine (mg/dl) 0.15 >0.05 N.sig.
Urinary albumin 0.26 >0.05 N.sig.
SLEAI score 0.84 <0.001** HS  




Nephritis in SLE is one of the most important 
causes of morbidity and mortality. One-third of 
patients with systemic lupus erythematosus (SLE) 
nephritis have flares despite the best treatment and 
still progress to end-stage renal disease12,13. 
TGF-β1 plays a dual role during the 
development and progression of immune-mediated 
inflammatory diseases. The enhanced TGF-β1 
production in tissues induces local fibrogenesis and 
ultimately causes fulminant organ damage14. 
Our study was performed on 25 children 
suffering from SLE: (13 of them presented 
clinically and through laboratory results by active 
nephritis, 12 were without nephritis). These 2 
groups were compared in plasma and urinary levels 
of  TGF-β1 with 20 healthy control subjects of 
matched age, sex and weight. 
The present study  showed a highly significant 
difference between patients with active nephritis 
and the healthy subjects in plasma TGF-β1 levels 
(significantly low in group Ι). While there was no 
significant difference between patients with silent 
nephritis and the control group. 
In fact, early studies revealed no significant 
differences of levels of TGF-β1 in serum between 
healthy control subjects and patients with inactive 
and active SLE15. 
 On the other hand, Sook et al.16 studied 
cytokines in 145 SLE  patients and 61 control. They 
found that plasma TGF-β1 was significantly higher 
in the controls than the patients (p<0.001). 
Also, Ohtsuka et al.17, reported no detectable 
TGFβ1 production in isolated T cells, but found no 
difference between TGF-β1 production of 
monocytes from normal and SLE patients. They 
found that in SLE and healthy controls, NK cells 
produced substantially more TGF-β1 than T cells.  
Kohut et al.18 showed that TGF-β1 mRNA 
production is defective in T and B cells isolated 
from SLE patients’ peripheral blood. In more than 
half of SLE patients T cells displayed undetectable 
levels of TGF-β1 mRNA. Nevertheless, they  found 
slightly increased total plasma TGF-β1 levels both 
in active and in inactive SLE patients. This may 
seem paradoxical, but NK cells, monocytes and 
other non lymphoid cells are also potential 
producers of TGF-β1 . 
Our results showed a significant positive 
correlation between serum TGF-β and C3,while 
there was a significant negative correlation between 
it and both serum creatinine, urinary albumin, anti 
ds-DNA and SLEDAI score. 
Hammad et al.19 agreed with our results and 
revealed a significantly decreased plasma TGF-β1 
levels in children with active SLE when compared 
to healthy controls. Moreover, plasma active TGF-
β1 levels correlated negatively with SLEDAI score. 
They suggest that decreased plasma TGF-β1 levels  
with subsequent insufficient exposure of T cells to 
TGF- β1 might be one of the factors responsible for 
impaired down regulation of B cells. Inhibition of 
complement (C3) synthesis by TGF-β1 may be  
associated with suppression of complement 
activation locally by blocking renal inflammation in 
response to high levels of latent TGF-β120. 
Also, Becker et al.21 agreed with our results as 
they found that a lower TGF-ß1 level correlates 
with disease activity, and severe organ damage in 
active SLE. 
Renal involvement has been reported in 
approximately two-thirds of  children and 
adolescents with SLE during the course of their 
disease. However, only 25–50% of unselected 
patients with lupus were reported to have 
abnormalities of urine or renal impairment early in 
their disease22. Increased glomerular TGF-β1 was 
found present and locally produced in samples of 
adults as well as children with SLE nephritis23. 
 Saxena et al.24 measured tissue concentration 
of TGF-β1 in kidneys in lupus mice and found that 
it correlated with the extent of chronic kidney 
disease. This relationship appears more robust when 
TGF- β1was measured in the urine of lupus mice. 
Urinary TGF-β1 levels strongly correlate with 
chronic kidney damage, particularly with 
tubulointerstitial disease and glomerulosclerosis. 
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Also, Sonkar and Singh25 found that TGF-β1 
was significantly high in chronic renal failure 
(CRF) patients as compared to acute renal failure 
(ARF), probably it is more associated with 
interstitial inflammation but it can differentiate 
CRF from ARF if cut off of 40 ng/ml is taken .  
Our results showed a significantly high levels 
of urinary  TGF-β1 in SLE patients (either with 
active or silent nephritis) relative to the control 
group. We proved a significant positive correlation 
between urinary TGF-β1and both anti dsDNA and 
SLEAI score, while there was a significant negative 
correlation between urinary TGF-β1 and C3. There 
was no correlation between urinary TGF-β1 with 
both serum creatinine and urinary albumin. 
This agreed with  Honkanen et al.26 who found 
a positive  correlation between urinary TGF-β1 
excretion and interstitial inflammation, denoting 
that interstitial inflammatory cells may be the 
source of urinary TGF-β1. 
On the contrary, in the study of Haramaki et 
al.27 interstitial inflammation was not present in 
patients with in IgA nephropathy . 
In a study performed by Muro et al.28, urinary 
TGF-β1 levels correlated with crescent formation, 
floccular adhesions and mesangial proliferation, but 
not with the degree of tubulo-interstitial fibrosis. 
We were against Hammad et al.19 who  found 
no significant correlation between urinary TGF-β1 
levels and SLEDAI or proteinuria and only plasma 
active TGF-β1 was negatively correlated with 
SLEDAI. They also found a positive correlation 
between urinary TGF- β1 levels and serum anti-ds 
DNA levels and a negative correlation between 
urinary TGF-β1 levels and serum C3 levels. 
 
.We conclude that in children with active SLE, 
lowered plasma TGF- β1 level may be a feature of 
systemic immune dysfunction, which may have a 
role in the pathogenesis of renal involvement in 
those patients. Urinary TGF-β1 plays a role in the 
clinical presentation of lupus nephritis and has a 
prognostic value for disease severity. However, 
further studies are recommended to evaluate the use 
of plasma and urinary TGF-β1 as alternative non 
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